There was a greater difference in disease progression and breast cancer survival when the HIF Pathway score was used than when HIF-1α protein was considered, supporting the use of the pathway score as a robust marker of HIF-1 transcriptional activity and, potentially, patient prognosis. Here, SETD2 is linked to breast cancer.